

In the International Preliminary Examination Report claims, please amend the claims as follows:

3. [Twice amended] Method according to claim[s] 1, [2,]
M6
characterized in that the used antibodies are MOC31 and BM7, or fragments thereof.

4. [Twice amended] Method according to claim[s] 1, [2,]
characterized in that the used antibodies are MOC31 and BM2 or 12H12, or fragments thereof.

5. [Twice amended] Method according to claim[s] 1, [2,]
characterized in that the used antibodies are MOC31 and 595A6, or fragments thereof.

9. [Twice amended] A preparation of two [I]immunotoxins to kill cells according to the method in claim 1, characterized in that it contains two immunotoxins directed to antigens present on malignant cells.

10. [Twice amended] A preparation [Immunotoxins] according to claim 9,
characterized in that the antibodies are selected among MOC31, and BM7, 595, BM2, 12H12 or combinations of these or fragments thereof and the toxin is native or recombinant Pseudomonas exotoxin A, or fragments thereof.

11. [Twice amended] Use of [the] a preparation of two immunotoxins according to claim 9, to produce a therapeutic agent against cancer.

Please renumber Claim 13 as Claim 12.